Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomecel-B in Hypoplastic Left Heart Syndrome (ELPIS)
NCT03525418Phase 2Active, not recruiting
- Sponsor
- Longeveron
- Start
- Feb 2018
- Primary completion
- Jun 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of laromestrocel in hypoplastic left heart syndrome (HLHS) (3 cohorts), sponsored by Longeveron. Primary endpoint: Incidence of Treatment-Emergent Serious Adverse Events at 1 year. Started Feb 2018; status: active, not recruiting.
02
Drugs
laromestrocel
03
Conditions
hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on NCT03525418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525418.